Serotonin Antagonists - Adverse effects
Research News and Information

Tuesday, March 16, 2010

Role of serotoninergic pathways in drug-induced valvular heart disease and diagnostic features by echocardiography.

21 Jun 2009 Serotonin plays a significant role in the development of carcinoid heart disease, which primarily leads to fibrosis and contraction of right-sided heart valves. Recently, strong evidence has emerged that the use of specific drug classes, such as ... Read more...

Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis.

24 May 2009 OBJECTIVES: Irritable bowel syndrome (IBS) is a chronic functional disorder. 5-Hydroxytryptamine (5-HT) is a key modulator of gastrointestinal sensorimotor function. Many patients have IBS that can be difficult to treat, which has led to the ... Read more...

Pindolol augmentation enhances response outcomes in first depressive episodes.

3 May 2009 Effectiveness of Pindolol addition to SSRIs is still a matter of debate. Recently, Geretsegger et al. [Geretsegger, C., Bitterlich, W., Stelzig, R., Stuppaeck, C., Bondy, B. and Aichhorn, W. (2008) Paroxetine with Pindolol augmentation: a ... Read more...

Latest indexed articles for 'Serotonin Antagonists - Adverse effects'

These are the very latest articles for this heading:

• Case records of the Massachusetts General Hospital. Case 31-2009. A 26-year-old man with abdominal distention and shock. 6 Oct 2009
• Role of serotoninergic pathways in drug-induced valvular heart disease and diagnostic features by echocardiography. 21 Jun 2009
• Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis. 24 May 2009
• Pindolol augmentation enhances response outcomes in first depressive episodes. 3 May 2009
• [Pharmacological and clinical profile of ramosetron hydrochloride (Irribow), a novel therapeutic agent for irritable bowel syndrome with diarrhea] 29 Apr 2009
• Coronary vasospasm and atrial fibrillation associated with ondansetron therapy. Mar 2009
• Neuroleptic malignant syndrome due to risperidone treatment in a child with Joubert syndrome. 27 Feb 2009
• Seizure associated with palonosetron. 11 Jan 2009
• Serotonin 5-HT2B receptor in cardiac fibroblast contributes to cardiac hypertrophy: a new therapeutic target for heart failure? 31 Dec 2008
• Ondansetron-induced aminotransferase level elevation: case report and review of the literature. 29 Nov 2008
• Randomized, placebo-controlled trial of risperidone for acute treatment of bipolar anxiety. 27 Nov 2008
• Agomelatine treatment of major depressive disorder. 23 Nov 2008
• Taste masking by spray-drying technique. 17 Nov 2008
• Hypothesis-driven medication discovery for the treatment of psychostimulant addiction. 30 Oct 2008
• [Conference of experts--short text. Management of postoperative nausea and vomiting. French Society of Anesthesia and Resuscitation] 23 Oct 2008
• Possible precipitation of migraine attacks with prophylactic treatment. 22 Oct 2008
• Palonosetron (Aloxi) and dexamethasone for the prevention of acute and delayed nausea and vomiting in patients receiving multiple-day chemotherapy. 5 Oct 2008
• The efficacy and safety of palonosetron compared with granisetron in preventing highly emetogenic chemotherapy-induced vomiting in the Chinese cancer patients: a phase II, multicenter, randomized, double-blind, parallel, comparative clinical trial. 28 Sep 2008
• Added ondansetron for stable schizophrenia: a double blind, placebo controlled trial. 11 Sep 2008
• Treating each and every depressed patient. 30 Aug 2008

See a longer list of these articles.

Technical information about 'Serotonin Antagonists'

Definition: Drugs that bind to but do not activate serotonin receptors, thereby blocking the actions of serotonin or serotonin agonists.

Registry Number: 0

Descriptor UI: D012702

Alternative terms: Serotonin Antagonists; Antagonists, Serotonin; 5-Hydroxytryptamine Antagonists; 5 Hydroxytryptamine Antagonists; Antagonists, 5-HT; Antagonists, 5 HT; 5-HT Antagonists; 5 HT Antagonists; Antagonists, 5-Hydroxytryptamine; Antagonists, 5 Hydroxytryptamine; Antiserotonergic Agents; Agents, Antiserotonergic; Serotonin Blockaders; Blockaders, Serotonin;

Related Mesh Headings: Serotonin Uptake Inhibitors;

Allowable Qualifiers: administration & dosage; adverse effects; analysis; blood; cerebrospinal fluid; chemical synthesis; classification; diagnostic use; economics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; poisoning; radiation effects; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications;

Tree Number: D27.505.519.625.850.850; D27.505.696.577.850.850;

Online Note: search SEROTONIN /antagonists & inhibitors 1968-77 & SEROTONIN 1966-67

History Note: 78,64-67

Technical Notes: GEN or unspecified; prefer specifics; differentiate from SEROTONIN UPTAKE INHIBITORS: read MeSH definition; do not confuse with SEROTONIN AGONISTS; DF: SEROTONIN ANTAG